Laird Norton Wetherby Trust Company’s INmune Bio INMB Stock Holding History

Laird Norton Wetherby Trust Company’s Portfolio INMB Stock Details INMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$56.5K	Buy	50,000 +5,000	+11%	+$7.13K	﹤0.01%	980
2025 Q4	$70.2K	Buy	45,000 +20,000	+80%	+$35.7K	﹤0.01%	1013
2025 Q3	$51.8K	Sell	25,000 -12,000	-32%	-$27.5K	0.01%	64
2025 Q2	$85.5K	Buy	37,000 +400	+1%	+$2.94K	0.01%	67
2025 Q1	$286K	Buy	36,600 +2,500	+7%	+$19.9K	0.05%	58
2024 Q4	$159K	Buy	34,100 +1,250	+4%	+$6.52K	0.02%	67
2024 Q3	$177K	Buy	32,850 +1,350	+4%	+$9.6K	0.02%	71
2024 Q2	$278K	Hold	31,500	–	–	0.04%	55
2024 Q1	$370K	Hold	31,500	–	–	0.05%	58
2023 Q4	$355K	Buy	+31,500	New	+$264K	0.04%	66

Other funds holding INMB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Laird Norton Wetherby Trust Company's INMB Position: Q1 2026 in Review

Laird Norton Wetherby Trust Company increased its INmune Bio (INMB) stake by 11% in Q1 2026, buying an estimated $7.13K and bringing the position to 50,000 shares worth $56.5K. The position accounts for ﹤0.01% of the portfolio, ranked #980.

Laird Norton Wetherby Trust Company first reported a position in INMB in Q4 2023 and has held it in 10 quarters since. The position peaked at $370K in Q1 2024. 82 funds tracked by Wall St. Rank hold INMB as of Q1 2026.

Laird Norton Wetherby Trust Company held 50,000 shares of INmune Bio worth $56.5K as of Q1 2026.
Laird Norton Wetherby Trust Company bought 5,000 INmune Bio shares in Q1 2026, an estimated $7.13K.
INmune Bio made up ﹤0.01% of Laird Norton Wetherby Trust Company's portfolio in Q1 2026, its #980 holding.
Laird Norton Wetherby Trust Company first reported a position in INmune Bio in Q4 2023 and has held it in 10 quarters since.
Laird Norton Wetherby Trust Company's INmune Bio position peaked at $370K in Q1 2024.
82 funds tracked by Wall St. Rank held INmune Bio as of Q1 2026.

Based on Laird Norton Wetherby Trust Company's 13F filing for Q1 2026, filed 15 May 2026.